Chronic effects of selective endothelin ETA or ETB receptor antagonist on cardiac dysfunction in the J-2-N cardiomyopathic hamsters

被引：0
|
作者：
Nishida, M
Hayashi, T
Ieshima, M
Eshiro, K
Akiyoshi, K
Takaoka, M
Matsumura, Y
机构：
[1] Osaka Univ Pharmaceut Sci, Dept Pharmacol, Osaka 5691094, Japan
[2] Osaka Med Coll, Dept Med 3, Takatsuki, Osaka 5691094, Japan
来源：
JAPANESE JOURNAL OF PHARMACOLOGY | 2002年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P795
引用
收藏
页码：260P / 260P
页数：1
相关论文
共 50 条
  • [21] Role of endothelin ETA and ETB receptor in the ischemia/reperfusion-induced cardiac dysfunction and norepinephrine overflow of isolated rat hearts
    Yamamoto, S
    Matsumoto, N
    Kanazawa, M
    Fujita, M
    Takaoka, M
    Gariepy, CE
    Yanagisawa, M
    Matsumura, Y
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 94 : 271P - 271P
  • [22] Vasodilator effects of the endothelin ETA receptor selective antagonist BMS-193884 in healthy men
    Dhaun, N
    Strachan, FE
    Newby, DE
    Johnston, NR
    Ford, NF
    Hammett, JL
    Palmisano, M
    Webb, DJ
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (06) : 611 - 622
  • [23] Differential effects of the mixed ETA/ETB-receptor antagonist bosentan on endothelin-induced bronchoconstriction, vasoconstriction and prostacyclin release
    Martin, C
    Held, HD
    Uhlig, S
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2000, 362 (02) : 128 - 136
  • [24] Differential effects of the mixed ETA/ETB-receptor antagonist bosentan on endothelin-induced bronchoconstriction, vasoconstriction and prostacyclin release
    Christian Martin
    Heinz-Dieter Held
    Stefan Uhlig
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2000, 362 : 128 - 136
  • [25] Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist
    Nishikibe, M
    Ohta, H
    Okada, M
    Ishikawa, K
    Hayama, T
    Fukuroda, T
    Noguchi, K
    Saito, M
    Kanoh, T
    Ozaki, S
    Kamei, T
    Hara, K
    William, D
    Kivlighn, S
    Krause, S
    Gabel, R
    Zingaro, G
    Nolan, N
    O'Brien, J
    Clayton, F
    Lynch, J
    Pettibone, D
    Siegl, P
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1999, 289 (03): : 1262 - 1270
  • [26] Selective endothelin ETA and dual ETA/ETB receptor blockade improves endothelial function in patients with type 2 diabetes and coronary artery disease
    Rafnsson, A.
    Shemyakin, A.
    Pernow, J.
    EUROPEAN HEART JOURNAL, 2013, 34 : 1060 - 1060
  • [27] Effects of a selective endothelin A (ETA) receptor antagonist on GBS-induced pulmonary hypertension in newborn piglets
    Peng, JH
    Ladino, J
    Hehre, D
    Bancalari, E
    Suguihara, C
    PEDIATRIC RESEARCH, 2003, 53 (04) : 432A - 432A
  • [28] Effects of L-749,329, an ETA/ETB endothelin receptor antagonist, in a porcine coronary artery injury model of vascular restenosis
    Huckle, WR
    Drag, MD
    Acker, WR
    Powers, M
    McFall, RC
    Holder, DJ
    Walsh, TF
    Schwartz, RS
    Greenlee, WJ
    Johnson, RG
    CIRCULATION, 2001, 103 (14) : 1899 - 1905
  • [29] The effects of TBC3214, a selective endothelin ETA receptor antagonist, on orthodontic tooth movement in rats
    Sprogar, S.
    Volk, J.
    Drevensek, M.
    Drevensek, G.
    EUROPEAN JOURNAL OF ORTHODONTICS, 2007, 29 (06) : 605 - 608
  • [30] Chronic (1 year) treatment with an endothelin receptor antagonist greatly improves survival in the hamsters with heart failure doe to cardiomyopathy: Increased expression of endothelin-1 mRNA in the failing heart of cardiomyopathic hamsters
    Miyauchi, T
    Yamauchi, R
    Kobayashi, T
    Hoshino, T
    Sakai, S
    Kikkawa, K
    Yabana, H
    Murata, S
    Goto, K
    Sugishita, Y
    CIRCULATION, 1998, 98 (17) : 82 - 82
12345